China has carried out negotiations on the National Reimbursement Drug List for eight consecutive years to expand medical insurance coverage, with the medical insurance funds spending 504.8 billion yuan (US$74.04 billion) on medicines under insurance coverage and benefiting 1.17 billion patient visits as of February, an official said Wednesday.